Taysha Gene Therapies’ (TSHA) Market Outperform Rating Reiterated at JMP Securities

JMP Securities restated their market outperform rating on shares of Taysha Gene Therapies (NASDAQ:TSHA) in a report released on Tuesday,Benzinga reports. The firm currently has a $5.00 price objective on the stock.

Other analysts also recently issued research reports about the company. Needham & Company LLC restated a “buy” rating and issued a $6.00 price target on shares of Taysha Gene Therapies in a research note on Tuesday. Cantor Fitzgerald restated an “overweight” rating and set a $7.00 price target on shares of Taysha Gene Therapies in a report on Tuesday. Canaccord Genuity Group dropped their price target on shares of Taysha Gene Therapies from $7.00 to $6.00 and set a “buy” rating on the stock in a research note on Wednesday, August 14th. Finally, Chardan Capital restated a “buy” rating and set a $7.00 price objective on shares of Taysha Gene Therapies in a research note on Tuesday, August 13th. Eight research analysts have rated the stock with a buy rating, According to MarketBeat.com, Taysha Gene Therapies currently has a consensus rating of “Buy” and a consensus price target of $6.38.

Taysha Gene Therapies Stock Up 2.7 %

NASDAQ:TSHA opened at $2.27 on Tuesday. The company has a debt-to-equity ratio of 0.35, a current ratio of 5.22 and a quick ratio of 5.22. The firm’s 50-day moving average price is $1.98 and its 200-day moving average price is $2.39. The company has a market capitalization of $465.22 million, a PE ratio of 3.60 and a beta of 0.44. Taysha Gene Therapies has a 1-year low of $1.19 and a 1-year high of $4.32.

Taysha Gene Therapies (NASDAQ:TSHA) last announced its quarterly earnings data on Monday, August 12th. The company reported ($0.09) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.10) by $0.01. Taysha Gene Therapies had a negative net margin of 888.18% and a negative return on equity of 168.91%. The business had revenue of $1.11 million for the quarter, compared to analysts’ expectations of $3.62 million. During the same quarter in the prior year, the company earned ($0.38) earnings per share. On average, equities analysts predict that Taysha Gene Therapies will post -0.35 EPS for the current fiscal year.

Institutional Trading of Taysha Gene Therapies

Institutional investors have recently made changes to their positions in the stock. MetLife Investment Management LLC lifted its position in Taysha Gene Therapies by 81.9% during the third quarter. MetLife Investment Management LLC now owns 76,037 shares of the company’s stock valued at $153,000 after purchasing an additional 34,243 shares during the period. Charles Schwab Investment Management Inc. raised its stake in Taysha Gene Therapies by 7.7% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 462,867 shares of the company’s stock valued at $930,000 after buying an additional 33,123 shares during the last quarter. Intech Investment Management LLC bought a new position in shares of Taysha Gene Therapies during the 3rd quarter valued at $85,000. GSA Capital Partners LLP boosted its stake in shares of Taysha Gene Therapies by 64.7% in the 3rd quarter. GSA Capital Partners LLP now owns 233,560 shares of the company’s stock worth $469,000 after buying an additional 91,755 shares during the last quarter. Finally, Los Angeles Capital Management LLC bought a new stake in shares of Taysha Gene Therapies in the third quarter worth $416,000. Hedge funds and other institutional investors own 77.70% of the company’s stock.

Taysha Gene Therapies Company Profile

Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.